News

US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)
The FDA said risks linked to CAR-T cell therapies can be effectively communicated through existing labeling, including boxed ...
PharmTech2h
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Sascha Berger, private biopharmaceutical investor; Shannon Eaker, CTO of Xcellbio; Edwin Stone, CEO of Cellular Origins; and ...
ASTCT’s Leadership Contributes to FDA Decision to Eliminate REMS for BCMA- and CD19-Directed Autologous CAR T Cell Immunotherapies
CHICAGO, IL / ACCESS Newswire / July 1, 2025 / The U.S. Food and Drug Administration (FDA) has removed the Risk Evaluation ...
Medical Dialogues3d
USFDA lifts Risk Evaluation and Mitigation Strategies for CAR T cell therapies
The U.S. Food and Drug Administration (USFDA) has announced that it has eliminated the Risk Evaluation and Mitigation ...
Security6d
Risk Assessment Methods and Mitigation Strategies for Physical Security
Learn how to integrate risk mitigation strategies into organizational policies and operational processes. Review real-world case studies showcasing successful risk assessment and mitigation ...
Cancer Therapy Advisor1d
FDA Removes REMS, Changes Other Restrictions for Breyanzi and Abecma
The FDA has approved updated labels for Breyanzi and Abecma, removing the REMS programs and reducing certain restrictions.
US FDA Eliminates Risk Evaluation and Mitigation Strategies for CAR-T Cancer Therapies
(Reuters) -The U.S. Food and Drug Administration said on Friday that it had eliminated the risk evaluation and mitigation ...
Reuters4d
US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies
The U.S. Food and Drug Administration said on Friday it had eliminated risk evaluation and mitigation strategies (REMS), a safety program to protect patients from risky drugs, for currently ...